中文产业新闻评分54Chinese source
诺和诺德与恒瑞医药就GLP-1/GIP双受体激动剂HRS-1596达成许可协议，潜在总交易额最高26亿美元
26 亿美元！诺和诺德拿下恒瑞GLP-1/GIP 双受体激动剂
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
26 亿美元！诺和诺德拿下恒瑞GLP-1/GIP 双受体激动剂
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.